Amy­lyx hires new CMO from Ul­tragenyx; Eliot Forster is back as a CEO af­ter F-star sale

→ With Amy­lyx Phar­ma­ceu­ti­cals’ ALS drug in full com­mer­cial swing, the Mass­a­chu­setts start­up has found a re­place­ment for its chief med­ical of­fi­cer. Camille Bedrosian will join the com­pa­ny from Ul­tragenyx, tak­ing the place of Patrick Yerami­an, whose re­tire­ment was an­nounced in De­cem­ber 2022. Bedrosian has made a ca­reer in rare dis­ease drug de­vel­op­ment, hav­ing pre­vi­ous­ly worked not on­ly at Ul­tragenyx but al­so Alex­ion, where she was al­so the CMO. The rare dis­ease an­gle is one Amy­lyx aims to fo­cus on as the FDA re­con­sid­ers how it views ALS and po­ten­tial new reg­u­la­to­ry and tri­al ac­cess bills make their way through Con­gress.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.